Issue link: https://www.e-digitaleditions.com/i/1546950
16 OctOber 2026 Inhalation effective therapies through improved pulmonary drug delivery. By the same token, the study clearly demonstrated the need to perform modeling work before designing a DPI, based on first principles. Nevertheless, further studies are required to include a broader range of inhalers and drugs, as well as additional add-on geometries and sizes. In addition, measurements on molded components are needed, as 3D-printed components may behave differently from an electrostatic point of view. Acknowledgement Project no. 00057 has been implemented with the support provided by the Ministry of Culture and Innovation of Hungary from the National Research, Development and Innovation Fund, financed under the 2021-1.1.4-GYORSÍTÓSÁV-2022 funding scheme. References 1. DeHaan WH, Finlay WH. Predicting extratho- racic deposition from dry powder inhalers. Journal of Aerosol Science 356: 309-331, 2004. 2. Chaugule V, Reis LG, Fletcher DF, et al. A varying- swirl design concept for dry powder inhalers. Journal of Aerosol Science 171: 106162, 2023. 3. Singh G, Tang P, Cheng S, et al. From laminar to turbulent flow in a dry powder inhaler: e effect of simple design modifications. International Journal of Pharmaceutics 616: 121556, 2022. large differences among devices arose from variations in flow conditions and aerosol size distributions. As shown in Figure 3, the flow around the exit of the Turbuhaler and Ellipta DPIs is highly turbulent without an add-on. By attaching an add-on, turbu- lence intensity decreased drastically. Turbulence lev- els also decreased in the case of the Breezhaler and NEXaler but the decrease was less significant due to the lower initial levels. To summarize the results of this work, Figure 5 depicts the maximum value of the achievable increase in the dose entering the lungs and the add-on type causing this enhancement. It is worth noting that add-ons should be tailored to the special shape of the mouth- piece of each inhaler, which can ensure stable attach- ment to the inhaler and safe use for patients. Such effort is in progress within our research group. Figure 6 shows the final forms of the add-ons for Breezhaler ® (upper items) together with the inhaler (lower left) and attached to it (lower right). For the remaining inhalers, the airtight connections still need to be finalized. Conclusions In conclusion, this work presented add-on shapes optimized through numerical techniques and vali- dated by in vitro experiments. e most encouraging outcome is that, for every patient's breathing capa- bility, at least one add-on exists that can increase the dose delivered to the lungs. At the same time, the negative values in Table 1 highlight that the choice of add-on must be tailored to the specific inhaler-drug combination and to the patient's inhalation profile; otherwise, a reduction in lung dose may occur. ese findings may support the development of more Figure 6 CAD renderings of add-ons designed to influence airflow and deposition of particles emitted from the Breezhaler ® DPI (top), alongside photographs of the 3D-printed cone_4 add-on, shown both detached from and attached to the inhaler (bottom).

